Volume 133, Issue 23



June 6, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Sickle red blood cells make thrombotic clots resistant to fibrinolysis. See the article by Faes et al.

Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease
Sickle cell disease significantly alters the composition of the clot in a mouse model of venous thrombosis, a finding which adds to our understanding of its prothrombotic effect. Entrapped sickled red blood cells increase fibrin deposition in venous thrombi and enhance clot resistance to fibrinolysis..

The chromatin-binding protein Phf6 restricts the self-renewal of hematopoietic stem cells
This work defines plant homeodomain finger protein 6 (Phf6) as a novel negative regulator of hematopoietic stem cell (HSC) self renewal, implicating inactivating PHF6 mutations in the pathogenesis of hematological malignancies. Notably, Phf6 ablation renders HSCs less responsive to inflammatory stress signals.

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
This Special Report is a consensus statement on the diagnosis and management of hemophagocytic lymphohistiocytosis, written by internationally known experts in the field. It fills a major clinical need for guidance on the emerging topic of adult hemophagocytic syndromes.

Simplifying the diagnosis of inherited platelet disorders? The new tools do not make it any easier
This Blood Spotlight addresses the issue of how thorough the diagnosis of hereditary platelet defects in everyday clinical practice should be.

Monoclonal gammopathy of undetermined significance
The authors comprehensively review the current body of literature on the biology of monoclonal gammopathy of undetermined significance (MGUS) and provide a rationale for the identification of high-risk MGUS patients who may be identified for clinical interventions prior to the development of overt multiple myeloma.

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.